Open AccessSecukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
Author(s) -
Antonio Costanzo,
Filomena Russo,
Marco Galluzzo,
Luca Stingeni,
Roberta Scuderi,
Leonardo Zichichi,
Manuela Papini,
Luisa Di Costanzo,
Andrea Conti,
Martina Burlando,
Andrea Chiricozzi,
Francesca Maria Gaiani,
Cristina Mugheddu,
Maria Letizia Musumeci,
Paolo Gisondi,
Stefano Piaserico,
Paolo Dapavo,
Marina Venturini,
Gianluca Pagnanelli,
Paolo Amerio,
Concetta Potenza,
Ketty Peris,
Franca Cantoresi,
Sara Trevisini,
Francesco Loconsole,
Annamaria Offidani,
Santo Raffaele Mercuri,
Viviana Lora,
Francesca Prignano,
Marta Bartezaghi,
G Oliva,
Elisabetta Aloisi,
R. Orsenigo
Publication year - 2021
Publication title -
acta dermato-venereologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.982
H-Index - 83
eISSN - 1651-2057
pISSN - 0001-5555
DOI - 10.2340/00015555-3816
Subject(s) - secukinumab , plaque psoriasis , psoriasis , medicine , psoriasis area and severity index , interleukin 17 , gastroenterology , dermatology , cytokine , psoriatic arthritis
Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.